Epidemiology of HPV genotypes in Uganda and the role of the current preventive vaccines: A systematic review

Table 5 HPV incidence in males participating in circumcision clinical trials

Author	Area, subjects	Study design	HPV test	HPV incident cases^c and rates^d for type-specific genotypes per 100 PYs			Proportions of type-specific incident infections at 24-month follow-up			Risk Ratio (RR) and 95% CI^† for HR* and multiple infections
Serwadda et al., 2010 [59]	Rakai district, uncircumcised HIV positive men aged 15-49 years; 103 men in intervention group and 107 men in control group	Randomized controlled trial	Roche HPV linear array	At 24 months HR-HPV incident cases^c Intervention group, 42 cases Control group, 57 cases Multiple infectionincident cases ^c Intervention group, 9.9 cases Control group, 24.7 cases			Incident proportions			At 24 months RR for HR-HPV types = 0.74 (0.54-1.01) RR for multiple infection = 0.04 (0.19-0.84).
								Intervention^d (%)	Control^d (%)
							HPV 16 HPV 18 HPV 45 HPV 51 HPV 52	5.8 4.3 4.1 5.4 10.1	14.9 11.1 10.3 13.9 8.2
Gray, et al. 2010 [60]	Rakai district, uncircumcised HIV negative men aged 15-49 years; 441 men in intervention and 399 men in control group	Randomized controlled trial	Roche HPV linear array	At 24 months HR-HPV incident cases ^c Intervention group, 19.7 cases Control group, 29.4 cases Multiple infection incident cases ^c Intervention group, 6.7 cases Control group, 14.8 cases Type specific incidence rates ^d						At 24 months RR for HR-HPV types = 0.67 (0.51-0.89) RR for multiple infections = 0.45 (0.28-0.73)
					Intervention	Control
					Incidence/100 PYs
				HPV 16 HPV 18 HPV 45 HPV 51 HPV 52	3.6 1.6 1.6 4.0 1.6	4.8 5.3 2.4 5.3 3.6

ISSN: 1750-9378